Allogeneic hematopoietic stem cell transplantation in Primary Cutaneous T Cell Lymphoma

Autor: Giovanna De Santis, Raffaella Cerretti, Massimiliano Postorino, Alessandro Lanti, Fabio Di Piazza, Alessandra Picardi, Daniela Nasso, Francesco Pisani, Enrico Scala, Maria Cantonetti, Eleonora Ceresoli, Gottardo De Angelis, Benedetta Mariotti, Laura Cudillo
Rok vydání: 2018
Předmět:
Male
medicine.medical_treatment
Graft vs Host Disease
Hematopoietic stem cell transplantation
Severity of Illness Index
Gastroenterology
Cohort Studies
0302 clinical medicine
hemic and lymphatic diseases
Secondary Prevention
Cutaneous T cell lymphoma
Hematology
Incidence
Graft vs Tumor Effect
Remission Induction
Hematopoietic Stem Cell Transplantation
General Medicine
Middle Aged
Lymphoma
T-Cell
Cutaneous
Italy
030220 oncology & carcinogenesis
Cord blood
Female
Adult
Risk
medicine.medical_specialty
Cancer Care Facilities
Disease-Free Survival
Donor lymphocyte infusion
Young Adult
03 medical and health sciences
Internal medicine
medicine
Humans
Transplantation
Homologous
Survival analysis
Aged
Neoplasm Staging
Retrospective Studies
Chemotherapy
business.industry
Cutaneous T-cell lymphoma
Allogeneic stem cell transplantation
medicine.disease
Survival Analysis
Lymphoma
business
Settore MED/15 - Malattie del Sangue
Follow-Up Studies
030215 immunology
Zdroj: Annals of Hematology. 97:1041-1048
ISSN: 1432-0584
0939-5555
DOI: 10.1007/s00277-018-3275-z
Popis: In our retrospective study, 16 patients affected by advanced cutaneous T cell lymphoma (CTCL) underwent allogeneic hematopoietic stem cell transplantation (HSCT). Two patients (12.5%) were in complete remission (CR), nine (56.3%) in partial remission (PR), and five (31.2%) with active disease. The patients were transplanted from an HLA-identical (n = 7) from a mismatched (n = 1) or haploidentical (n = 1) sibling, from matched unrelated donor (n = 5), or from a single cord blood unit (n = 2). Conditioning regimen was standard myeloablative in 6 patients and at reduced intensity in 10. Seven patients died from non relapse mortality (NRM) and four patients relapsed or progressed, three of them achieved a second CR after donor lymphocyte infusion (DLI) or chemotherapy plus DLI. To date, with a median follow-up of 76 months (range 6-130), nine patients are alive, eight in CR, and one with active disease. Overall survival (OS) and disease-free survival (DFS) at 1 and 10 years are 61% (95% CI 40-91%) and 54% (95% CI 33-86%), 40% (95% CI 22-74%), and 34% (95% CI 16-68%), respectively. The time from diagnosis to transplant seems to influence negatively both OS (log-rank p
Databáze: OpenAIRE
Externí odkaz: